<DOC>
	<DOCNO>NCT00178841</DOCNO>
	<brief_summary>The purpose trial determine combination therapy rosiglitazone bexarotene might synergistic effect treatment patient CTCL .</brief_summary>
	<brief_title>Combination Drug Study Bexarotene Rosiglitazone Treat CTCL</brief_title>
	<detailed_description>Treatment option CTCL include skin-directed systemic therapy . Topical treatment effective early-stage disease localize skin . However , disease involve lymph node visceral site palliate rarely cure , even aggressive regimen systemic chemotherapy . Unfortunately , current treatment option stage provide short term response . Thus , important additional therapy investigate manage malignancy . Bexarotene approve FDA treatment Cutaneous T-Cell Lymphoma ( CTCL ) .Bexarotene bind RXR ( Retinoid X Receptor ) inside cell , receptor form heterodimers multitude nuclear receptor . One PPARÎ³ ( Peroxisome Proliferator Activator Receptor Gamma ) , nuclear receptor bind Rosiglitazone.Rosiglitazone FDA approve antidiabetic agent Thiazolidinedione class . Rosiglitazone increase insulin sensitivity useful treatment type 2 diabetes . In vitro data suggest rosiglitazone bexarotene may act synergistically induce apoptosis cell line derive patient cutaneous T cell lymphoma ( CTCL ) . This pilot study investigate possible synergism small cohort patient stable progressive CTCL already treat bexarotene .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Patients biopsy proven persistent recurrent cutaneous cell lymphoma ( CTCL ) Stage IAIVA Patients pathologic proven diagnosis CTCL document patient history . Patient preserve organ function . Patient ECOG performance status 0 2 . Women childbearing potential screened pregnancy prior treatment utilize effective contraceptive method ( e.g . barrier ) treatment period . Patients age 18 willing able provide Informed Consent The patient take Targretin capsule least last 4 month dose remain relatively stable . The patient stable progressive disease past 4 month . Patient adequate laboratory parameter liver kidney function . Patients CD30+ Anaplastic Large Cell Lymphoma Patients pathology consistent peripheral Tcell lymphoma . Patients Stage IVB ( visceral involvement CTCL ) . Patients history Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C infection . Patients diagnosis congestive heart failure . Patients exhibit significant edema unstable cardiovascular disease . Patients fast triglyceride level great 500mg/dl . Patients start new treatment CTCL past 4 month . Pregnant woman exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>CTCL</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Sezary Syndrome</keyword>
	<keyword>Bexarotene</keyword>
	<keyword>Targretin</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Avandia</keyword>
</DOC>